Publications

Found 54 results
Filters: Author is Beltran, Himisha  [Clear All Filters]
2014
Galletti G, Matov A, Beltran H, Fontugne J, Mosquera JMiguel, Cheung C, MacDonald TY, Sung M, O'Toole S, Kench JG et al..  2014.  ERG induces taxane resistance in castration-resistant prostate cancer.. Nat Commun. 5:5548.
Beltran H, Kaur G, de España CGarcías, Tagawa ST.  2014.  Exploring the role of anti-angiogenic therapies in prostate cancer: results from the phase 3 trial of sunitinib.. Asian J Androl. 16(4):568-9.
Lin D, Wyatt AW, Xue H, Wang Y, Dong X, Haegert A, Wu R, Brahmbhatt S, Mo F, Jong L et al..  2014.  High fidelity patient-derived xenografts for accelerating prostate cancer discovery and drug development.. Cancer Res. 74(4):1272-83.
Terry S, Beltran H.  2014.  The many faces of neuroendocrine differentiation in prostate cancer progression.. Front Oncol. 4:60.
Chakravarty D, Sboner A, Nair SS, Giannopoulou E, Li R, Hennig S, Mosquera JMiguel, Pauwels J, Park K, Kossai M et al..  2014.  The oestrogen receptor alpha-regulated lncRNA NEAT1 is a critical modulator of prostate cancer.. Nat Commun. 5:5383.
Gao D, Vela I, Sboner A, Iaquinta PJ, Karthaus WR, Gopalan A, Dowling C, Wanjala JN, Undvall EA, Arora VK et al..  2014.  Organoid cultures derived from patients with advanced prostate cancer.. Cell. 159(1):176-87.
Epstein JI, Amin MB, Beltran H, Lotan TL, Mosquera J-M, Reuter VE, Robinson BD, Troncoso P, Rubin MA.  2014.  Proposed morphologic classification of prostate cancer with neuroendocrine differentiation.. Am J Surg Pathol. 38(6):756-67.
Park K, Chen Z, MacDonald TY, Siddiqui J, Ye H, Erbersdobler A, Shevchuk MM, Robinson BD, Sanda MG, Chinnaiyan AM et al..  2014.  Prostate cancer with Paneth cell-like neuroendocrine differentiation has recognizable histomorphology and harbors AURKA gene amplification.. Hum Pathol. 45(10):2136-43.
Prandi D, Baca SC, Romanel A, Barbieri CE, Mosquera J-M, Fontugne J, Beltran H, Sboner A, Garraway LA, Rubin MA et al..  2014.  Unraveling the clonal hierarchy of somatic genomic aberrations.. Genome Biol. 15(8):439.
2012
Beltran H, Park K, Tagawa ST, Macdonald T, Nanus DM, Mosquera JMiguel, Rubin MA.  2012.  Association of concurrent AURKA and MYCN amplification in primary prostate adenocarcinoma with the development of lethal neuroendocrine prostate cancer (NEPC).. J Clin Oncol. 30(5_suppl):120.
Beltran H, Tagawa ST, Park K, Macdonald T, Milowsky MI, Mosquera JMiguel, Rubin MA, Nanus DM.  2012.  Challenges in recognizing treatment-related neuroendocrine prostate cancer.. J Clin Oncol. 30(36):e386-9.
Lapuk AV, Wu C, Wyatt AW, McPherson A, McConeghy BJ, Brahmbhatt S, Mo F, Zoubeidi A, Anderson S, Bell RH et al..  2012.  From sequence to molecular pathology, and a mechanism driving the neuroendocrine phenotype in prostate cancer.. J Pathol. 227(3):286-97.
Demichelis F, Setlur SR, Banerjee S, Chakravarty D, Chen JYun Helen, Chen CX, Huang J, Beltran H, Oldridge DA, Kitabayashi N et al..  2012.  Identification of functionally active, low frequency copy number variants at 15q21.3 and 12q21.31 associated with prostate cancer risk.. Proc Natl Acad Sci U S A. 109(17):6686-91.
Beltran H, Park K, Tagawa ST, Yelensky R, Lipson D, Frampton G, Stephens PJ, Cronin MT, Nanus DM, Mosquera JMiguel et al..  2012.  Identifying cancer mutations in neuroendocrine prostate cancer (NEPC) through massively parallel DNA sequencing of formalin-fixed paraffin-embedded (FFPE) tissue.. J Clin Oncol. 30(5_suppl):110.
Collins CC, Volik SV, Lapuk AV, Wang Y, Gout PW, Wu C, Xue H, Cheng H, Haegert A, Bell RH et al..  2012.  Next generation sequencing of prostate cancer from a patient identifies a deficiency of methylthioadenosine phosphorylase, an exploitable tumor target.. Mol Cancer Ther. 11(3):775-83.